Viridian Therapeutics Inc
$ 16.35
1.30%
12 Jun - close price
- Market Cap 1,805,493,000 USD
- Current Price $ 16.35
- High / Low $ 16.68 / 16.18
- Stock P/E N/A
- Book Value 4.92
- EPS -3.35
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.58 %
- 52 Week High 34.29
- 52 Week Low 13.18
About
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$33.94
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-05 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-12 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-13 | 2023-08-08 |
| Reported EPS | -0.9 | -1.08 | -0.34 | -1 | -0.87 | -0.81 | -1.15 | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 |
| Estimated EPS | -1.09 | -0.9558 | -0.94 | -1.03 | -0.98 | -1.0442 | -1.05 | -0.92 | -1.1 | -1.03 | -1.24 | -1.26 |
| Surprise | 0.19 | -0.1242 | 0.6 | 0.03 | 0.11 | 0.2342 | -0.1 | -0.1 | 0.31 | -0.32 | 0.15 | -0.01 |
| Surprise Percentage | 17.4312% | -12.9944% | 63.8298% | 2.9126% | 11.2245% | 22.4287% | -9.5238% | -10.8696% | 28.1818% | -31.068% | 12.0968% | -0.7937% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VRDN
2026-06-09 21:37:55
Viridian Therapeutics, Inc. (VRDN) anticipates commercial approval for its product by June 30, supported by fully operational launch teams and a trained sales force targeting 2,000 core prescribers. The company highlights its differentiated clinical data and subcutaneous options, positioning its portfolio for wide adoption in both active and chronic thyroid eye disease. This information is based on a Goldman Sachs conference transcript.
2026-06-07 21:40:16
Viridian Therapeutics recently repaid a US$55.1 million term loan ahead of schedule and raised US$125 million through an equity offering. This move swaps expensive debt for equity dilution, improving near-term financial flexibility but not changing the core investment narrative, which remains tied to upcoming milestones for its thyroid eye disease pipeline. While the debt repayment tidies the balance sheet, the company still faces heavy cash burn, minimal revenue, and significant clinical, regulatory, and launch execution risks.
2026-06-04 21:10:43
RBC Capital increased its price target for Viridian Therapeutic (NASDAQ:VRDN) to $34 from $30, maintaining an Outperform rating. This adjustment follows strong trial data for its chronic thyroid eye disease treatment, Ele', which exceeded expectations. The company also announced a $250 million capital raise to support its commercialization efforts and has a PDUFA date for Veli' set for June 30.
2026-06-03 23:09:11
Viridian Therapeutics (VRDN) is preparing for the commercial launch of its TED drug in 2026, following a PDUFA date in June 2026. The company anticipates strong market expansion with both IV and subcutaneous options, aiming for broad access for patients. This initiative focuses on both active and chronic TED cases, supported by a robust financial strategy.
2026-06-03 10:40:16
Viridian Therapeutics, Inc. (VRDN) filed an 8-K report detailing the results of its 2026 Annual Meeting of Stockholders. Shareholders approved the election of two Class II directors, Tomas Kiselak and Jennifer K. Moses, the ratification of KPMG LLP as the independent registered public accounting firm, and, on an advisory basis, the compensation of named executive officers. The board also adopted an annual frequency for the advisory say-on-pay vote, aligning with stockholder preference.
2026-05-30 19:09:53
Viridian Therapeutics has fully repaid its US$55.10 million Hercules term loan and secured a manufacturing agreement with WuXi Biologics for its drug veligrotug. These actions indicate a strategic shift towards reducing debt and preparing for potential product launches, aiming to improve financing flexibility and operational readiness. However, they also highlight increased focus on Viridian's cash burn and the need for future funding if commercialization is slower than anticipated.
